top of page



We use our proprietary platform technology to create nucleic acid drugs that are optimized for the treatment of diseases.

PURMX's solution is to fine-tune a large number of target genes to create small RNA nucleic acid drugs with unprecedented therapeutic efficacy.

PURMX already possesses a large amount of functional RNA screening data, which is being further expanded.

The first stage of innovative nucleic acid medicine seeds is MIRX002.

MIRX002 seeds have already completed non-clinical trials and are being tested in Japan for malignant pleural mesothelioma from 2021 in an investigator-initiated clinical trial.

Global clinical trials for malignant pleural mesothelioma and head and neck cancer are planned to be conducted in the U.S., Australia, and Japan from 2024.

bottom of page